Sage Therapeutics (SAGE)
(Real Time Quote from BATS)
$14.61 USD
+0.92 (6.72%)
Updated Apr 29, 2024 01:26 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 41 - 60 ( 152 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Regulatory Shift for Zuranolone - We Think In A Good Way
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Does Skylark''s Success Complete the Zuranolone Puzzle? Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - Let''s Enjoy A Positive Update For A Moment - Zuranolone SKYLARK Hits
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Uneventful 4Q as Zuranolone NDA Submission Gets Rolling
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
As Zuranolone Rolls Ahead, Looking Forward to SKYLARK Mid-2022
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Quiet 4Q21 Call Ahead of Zuranolone Rolling NDA This Year; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
CORAL Hits Primary Endpoint But Data Raises Many More Questions Than It Answers; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
CORAL Hits Primary Endpoint; Debate Likely To Persist
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Rx for Portfolios, Part 1: Companies With Transformative Clinical Readouts Fast Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
FutureCast: SAGE-718 LUMINARY Data Arrives - On To CORAL
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Five Key Takeaways From Sages Third Annual FutureCast R&D Event; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D